Georgia's Online Cancer Information Center

Find A Clinical Trial

Multiple Phase 1 Safety Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed / Refractory Hematologic Malignancies

Status
Active
Cancer Type
Hodgkin Lymphoma
Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
Trial Phase
Phase I
Eligibility
18 Years and older, Male and Female
Study Type
Treatment
NCD ID
NCT01592370
Protocol IDs
CA209-039 (primary)
NCI-2012-02776
Study Sponsor
Bristol-Myers Squibb

Summary

The purpose of this study is to determine the side effects of treatment with Nivolumab by itself or in combination in patients with relapsed / refractory lymphoma or multiple myeloma.
Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.